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AIBSTRACT A DNA sequence encoding the entire pre-S2
region (amino acids 120-174; serotype ayw) ofhuman hepatitis
B virus envelope protein has been inserted into the lacZ gene of
the plasmid pSKS105 yielding a recombinant, pWS3. Lac+
colonies of the Escherichua coli M182 A(lacIOPZYA), isolated
after transformation with pWS3, produced a pre-S2
peptide-13-galactosidase fusion -protein. This fusion protein,
which comprised as much as 3% of the total bacterial protein,
was purified to >90% homogeneity by affinity chromatogra-
phy on p-aminophenyl-.3D-thiogalactoside-Sepharose. It is
immunoprecipitable with rabbit antibodies to a synthetic
peptide corresponding to amino acids 12-145 of the pre-S2
region of serotye adw [pre-S(120-145)] or with antibodies to
hepatitis B virusn pre-S(120-145) completely blocked the bind-
ing of either antibody to the pre-S2 peptide.-(galactosidase
fusion protein. These results indicate that there are antigenic
determinants on the fusion protein that are closely related to,
if not identical to, determinants on synthetic pre-S(120-145)
and on pre-S2 sequences of native hepatitis B. virus particles.
Thus, bacteria transformed with pWS3 can provide an abun-
dant source of pre-S2--j-galactosidase fusion protein, which
may prove useful either as a diagnostic reagent possessing
marker enzyme activity suitable for ELISA tests or as an
inmunogen with potential to contribute to active prophylaxis
of hepatitis B.
of components detected in earlier studies on the protein
composition of the HBV envelope and of HBsAg.
Although the pre-Sl and pre-S2 sequences have a relatively
low abundance in HBV or HBsAg isolated from the serum of
HBV carriers, their biological role has already been explored
by using appropriate polyclonal or monoclonal antibodies
against HI3V (7, 8), synthetic peptides (9), and proteins
synthesized in cells transfected with expression vector con-
taining the total S region or large portions of pre-S (10, 11).
For example, the amino acid sequences,encoded in the pre-S1
and pre-S2 regions have been shown to be involved in specific
binding of HBV (HBsAg) to the surface of human hepa-
tocytes (12). The amino acid sequence ofpre-S2 has also been
found to bind human and chimpanzee glutaraldehyde cross-
linked polyalbumin (11, 13, 14). In addition, it has been
shown that the 26 NH2-terminal amino acids (120-145) of the
pre-S2 region [pre-S(120-145)] correspond to a dominant
sequential antigenic determinant of HBV and HBsAg (9).
However, as yet, a convenient source for the large amounts
of pure full-length pre-S sequences essential for further
elucidation of the function of the pre-S regions has not been
available. In this report, we describe the pioduction, purifi-
cation, and immunochemical characterization of a pre-S2-f3
galactosidase fusion protein (pre-S2-Gal) synthesized as a
major protein component in transformed kscherichia coli.
Four open reading frames have been identified on the
transcript of the L strand of the hepatitis B virus (HBV)
genome-S, P, C, and X (reviewed in ref. 1). Region C codes
for the major protein of the virus nucleocapsid [hepatitis B
core antigen (2, 3)], region P is assumed to code for the viral
polymerase, and region X codes for a protein that has not yet
been detected in mature virus particles bit has been detected
in infected tissues (4). The region S codes for the surface
proteins of HBV (HBsAg). Although this region has the
potential to direct the synthesis of a protein 389-400 amino
acids long, depending on serotype (5), the predominant
protein component found in the HBV envelope or in 22-nm
subviral particles contains only 226 amino acids and is the
product of gene S, which starts within the S region with the
methionine codon at nucleotide 155 (1). This methionine
codon is preceded in the S region by two other methionine
codons at nucleotides 3172 and 2848,1 Which define the limits
of the pre-S2 and pre-Si regions and encode sequences of 55
and 108-119 amino acids, respectively. Thus, transcripts of
the entire S region could direct synthesis of three distinct
proteins that share the same 226 COOH-terminal amino
acids. Glycosylation of these proteins results in the multitude
MATERIALS AND METHODS
Bacterial Strains and Plasmids. JM83 ara&(lac pro) StrA thi
(08~dlacIq, ZAM15) (15) and pUC8 (16) were obtained from
Bethesda Research Laboratories, and M182 A(Iac IPOZYA)-
X74 galU galK strAr (17) and pSKS105 (18) were the kind
gifts of M. J. Casadaban. pTHBV-1, a recombinant plasmid
containing a head-to-tail dimer of a IBV genome (subtype
ayw), was constructed as described in ref. 6.
Isolation, Detection, and Pdrification of ,3-Galactosidase and
pre-S2-Gal. For preparation of lysates, bacteria from late-
logarithmic phase or stationary cultures were pelleted and
suspended in 1/20th of the culture volume in buffer contain-
ing 0.5 mg oflysozyme per ml, 0.1 M Tris HCl (pH 8), 0.1 mM
phenylmethylsulfonyl fluoride, 5 mM EDTA. After three
cycles of freeze-thawing, the suspension was centrifuged at
10,000 x g for 10 min and the supernatant was assayed for
3-galactosidase activity (19, 20). Proteins with f-galactosi-
dase activity were purified by affinity chromatography on
p-aminophenyl-,3-D-thiogalactoside-Sepharose prepared as
described by Ullmann (21). The proteins present in various
Abbreviations: HBV, hepatitis B virus; HBsAg, hepatitis B surface
antigen; pre-S2-Gal, fusion protein of pre-S2 peptide (amino acids
120-174 plus Met 175) with f-galactosidase.iNumbering of bases in the HBV sequences of pTHBV-i has been
changed from that used in ref. 6 to that used in ref. 1.
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fractions were analyzed by NaDodSO4/polyacrylamide slab
gel electrophoresis (22).
Immunological Detection of pre-S2-Gal. pre-S2-Gal was
detected by an immunoassay analogous to that described for
the reaction between rabbit anti-pre-S(120-145) and pre-S
(120-145) conjugated with ,-galactosidase (9). Briefly, serial
dilutions of bacterial lysates (50 1.l in 0.14 M NaCl/0.01 M
TrisHCl, pH 7.2/0.02% NaN3/10 mg of bovine serum
albumin per ml) were mixed with 450 1Ld of rabbit anti-pre-
S(120-145) diluted 1:180 in the same buffer. The mixture was
incubated for 30 min at 37TC; 100 pll of a 10% suspension of
Staphylococcus aureus bearing protein A (The Enzyme
Center, Boston) was added and, after 30 min at room
temperature, the bacteria were pelleted by centrifugation and
washed twice. /3-Galactosidase activity in the immune com-
plex was determined fluorometrically (20), and results were
corrected for nonspecific adsorption of 3-galactosidase in the
presence of diluted normal rabbit serum.
Enzymes and Chemicals. Restriction endonucleases, link-
ers, T4 ligase, and Klenow fragment of DNA Pol I were
purchased from New England Biolabs and were used accord-
ing to the manufacturer's recommendations. o-Nitrophenyl-
(3-D-galactopyranoside, 4-methylumbelliferyl-/3-D-galacto-
side, and P3-galactosidase were obtained from Sigma.
RESULTS
Construction of Plasmids (Fig. 1). The plasmid pUC8 (16)
was linearized by digestion at its unique Acc I site. The
staggered ends were filled in by polymerization using the
Klenow fragment of E. coli polymerase I. The plasmid was
then recircularized by ligation with T4 ligase and recloned.
The resulting plasmid (pUC8a) was digested with Pst I, which
cuts within the open reading frame for the lacZ' gene, and it
was blunt-ended by using the 3' -- 5' exonuclease of the
Klenow fragment. Sph I linkers were added and the plasmid
was recircularized by ligation after digestion with Sph I. This
construction (pUC8b) resulted in restoration of the correct
reading frame for the lacZ' gene and provided an additional
ATG sequence in phase with and 39 bases downstream from
the ATG sequence that marks the start of the Z' gene reading
frame. A 165-base-pair Nia III restriction fragment (bases
3174-157)' from pTHBV-1 (6) containing the entire sequence
ofthe pre-S2 region was inserted into the Sph I site ofpUC8b.
Two plasmids were isolated: pWS1, which contained the
insert in the proper orientation for the production of a fusion
protein of pre-S2 (amino acids 120-174 plus the first methio-
nine of the S gene) and 3-galactosidase; and pWS2, which
contained the insert in reverse orientation. The plasmid
pWS3 was constructed by ligating the 187-base-pair BamHI/
HindIII fragment of pWS1 that contained the pre-S2 se-
quences with BamHI- and HindIII-cleaved pSKS105 (18).
The structure of all recombinant plasmids was confirmed by
restriction analysis (not shown).
Expression of (3-Galactosidase and pre-S2-Gal in JM83 Cells
Transfected with pWS1 and pWS2. pUC8 directs synthesis of
an NH2-terminal fragment of P3-galactosidase that romple-
ments the COOH-terminal fragment of /3-galactosidase pro-
duced by JM83 cells. Thus, colonies of JM83 cells trans-
formed with this plasmid can be readily distinguished from
untransformed cells by their ability to form blue rather than
white colonies on agar containing the chromogenic 3-galac-
tosidase substrate, 5-bromo-4-chloro-3-indolyl f3-D-galacto-
side (23). JM83 cells transformed with either pWS1 or pWS2
gave rise to blue colonies with approximately the same
frequency as those transformed with pUC8 (data not shown).
Quantitation of active (3-galactosidase in lysates of cultures
grown out from two representative colonies, one transformed
with pWS1, the other with pWS2, demonstrated that inser-
tion ofpre-S2 sequences into the lacZ' gene ofpUC8 in either
FIG. 1. Construction of pWS1, pWS2, and pWS3. Sequences
from the lacZ gene are indicated by an open box; sequences
corresponding to the pre-S2 sequence of the HBV S region by a solid
box; the HBV S gene by a cross-hatched box, and pBR322 sequences
by a line. Arrows indicate the direction of transcription of HBV S
sequences and lacZ sequences. Restriction endonuclease cleavage
sites are abbreviated as follows: B, BamHI; A, Acc I; Ps, Pst I; H,
HindIII; N, Nia III; S, Sph I.
orientation still allowed efficient complementation of the
lacZAM15 gene product ofJM83 cells, although the levels of
active enzyme were lower in pWS2 transformed cells than in
pWS1 and pUC8 transformants (Table 1). However, when
proteins from the transformed cells were precipitated with
anti-pre-S(120-145) and Staphylococcus protein A, /3-galac-
tosidase activity was detectable only in precipitates from
JM83 cells carrying pWS1. This demonstrated (i) that the
anti-pre-S(120-145) antibodies did not recognize -galacto-
sidase and (ii) that pre-S2 sequences must be properly
oriented with respect to lacZ' sequences for production of a
fusion protein that can be recognized by antibodies specific
for pre-S(120-145).
Immunochemical Characterization and Quantitation of the
pre-S2-Gal. Both anti-pre-S(120-145) and antiserum against
HBV particles from which detectable antibodies against the
S protein had been removed (7) recognized pre-2-Gal
produced by JM83 cells transformed with pWS1 but failed to
react with proteins from JM83 cells transformed with pWS2
(Fig. 2). The reaction between the fusion protein and anti-
pre-S(120-145) (Fig. 3A) and the reaction between the fusion
protein and antibodies to the pre-S epitopes of native HBV
Biochemistry: Offensperger et al.
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Material
Expression of 3-galactosidase and pre-S2-Gal in E. coli for pre-S2 sequences in a fusion protein, the concentration of
pre-S2-Gal t pre-S2-Gal in lysates ofbacteria transformed with pWS1 was
To~tal -galactosidase, fluorescence units estimated by determining the concentration of synthetic
units per ml of lysate* per al of lysate peptide required for 50% inhibition of antibody binding bypre-S2-Gal (Fig. 3A). The sample tested in that experiment
>0.3 0.03 contained =10 ng per 20 ,Al of synthetic pre-S(120-145). SinceCs 135 0.04 pre-S(120-145) has a molecular weight of 2945, it could be(Si 92 2.8 calculated that the concentration of pre-S2-Gal in the bac-
OS2300.026 terial lysate was 0.17 AuM, which indicates that a late-
shown are from a typical experiment. Levels of 3-galac- logarithmic phase culture of JM83/pWS1 cells contains -40
and pre-S2-Gal activity found in six to seven different Ag Qf pre-S2 per liter.
.om the same bacterial strains did not vary by more than High Yield Production and Purification of a Pre-S2-Gal.
Although the experiments described above clearly demon-in lysate was determined directly as described in ref. 19. strated the feasibility of producing a pre-S2 fusion proteinIt of ,B-galactosidase is defined as the amount capable of w th a p o n p
zing 1 nmol of o-nitrophenyl-l3-p-galactopyranoside per min
Tqhe protein content of the lysate estimated from A,0 n low yield of pre-S2-Gal from JM83/pWS1 cells prompted us
g/ml. to construct a recombinant between the pre-S2 sequences
in lysate proteins precipitated with anti-pre-S(120-145)and and pSKS105, a plasmid known to lead to highly efficient
)coccus protein A measured as described in ref. 20 using production of f-galactosidase in the Lac- E. coli, M182 (18).
1-umbelliferyl-,-D-galactoside as substrate. Arbitrary fluo- To ensure preservation ofthe orientation ofpre-S2 sequences
units = 400 x (fluorometer digital readout/fluorometer with respect to the lacZ gene, a 187-base-pair BamHI/
ty range). Fluorescence units per ml of lysate precipitated Hin4III fragment of pWS1 containing the entire pre-S2
mal rabbit serum and Staphylococcus protein A were pWS1 sequence along with flanking lacZ sequences was substituted
pWS2 = 0.020. for the corresponding BamHI/HindIII flanked lacZ se-
quences of pSKS105 (pWS3; Fig. 1). M182 cells transformed
e proteins (Fig. 3B) were both efficiently and com- with pWS3 were identified by their ability to form blue rather
inhibited by synthetic pre-$(120-145) and by HBV than' white colonies on 5-bromo-4-chloro-3-indolyl P3-D-
This indicated a close Immunological relationship, galactoside plates. Cell cultures derived from these colonies
identity, of epitopes present on the sequence of the were tested for content of active P3-galactosidase and for
terminal amino acids of pre-S2, regardless ofwhether production of pre-S2-Gal. A typical culture of M182/pWS3
re located withinanative envelope protein, pre-S2- cells in late-logarithmic or stationary phase yielded
,he synthetic peptide itself. Furthermore, the finding =7,000,000 units or 200 mg of 3-galactosidase per liter.
thetic pre-S(120-145) completely inhibited the reac- [Calculated from the activity of a standard ,B-galactosidase
veen pre-S2-Gal and antibodies to the pre-S region of preparation of known concentration assayed under identical
velope protein suggested. that the NH2-terminal half conditions (19). This calculation was not made for JM83/
,2 is immunologically dominant and that the contri- pWS1 cells on the assumption that it would lead to an
tf the COOH-terminal half of pre-S2 to the antigenic- underestimation of content of the f-galactosidase formed by
i.. complementation in JM83.] Since a fusion protein betweenimmunogenicity of the HBV envelope proteins I 3-galactosidase (Mr, 116,090) and pre-S2 (Mr, #6000) is 5%Ltively small. by weight pre-S2, the cells have produced an estimated 10 mg
.passumption that the binding capacity of anti-pre- of pre-S2 peptide per liter. This value agrees quite well with
45) was equivalent for synthetic pre-S(120-145) and the content of pre-S2 estimated from a determination of the
concentration of pre-S(120-145) tequired for 50% inhibition
of anti-pre-S(120-145) binding by M182/pWS3 pre-S2-Gal (6
mg per liter of culture; data not shown).
Affinity Purification of Pre-S2-Gal. Pre-S2-Gal proved to
be a major component of unfractionated ly$ate from M182/
pWS3 cells. It was readily detectable as a Coomassie blue-
stained protein species absent from extracts of untrans-
formed M182 cells (Fig. 4a). The identity between this new
protein species and the pre-S2-Gal was confirmed by immu-
noprecipitation with anti-pre-S(120-145) and Staphylococxus
protein A (Fig. 4b, lane 1). With the appropriate concentra-
tion of anti-pre-S(120-145), pre-S2-Gal could be quantita-
tively precipitated (data not shown). However, no protein
with the electrophoretic mobility of either pre-S2-Gal or
/3-galactosidase was detected in immunoprecipitates of lys-
ates from M182 cells carrying pSKS105 without the pre-S2
insert (Fig. 4b, lane 2).
To purify pre-2-Gal, the lysate from M182/pWS3 cells
was passed over a column packed with p-aminophenyl-,B-D-
o'10 20 30 40 50 thiogalactoside-Sepharose. The 3-galactosidase activity was
quantitatively bound to the column and could be tluted with
Bacterial lysate (/l) buffer containing 100 mM sodium borate (pH 10), 10 mM
2-mercaptoethanol (Table 2). This one-step procedure gave a
'. Immunoassay of pre-S2-Gal precipitated with rabbit - ** * *Immuoassyofpre- e te th75-fold purification of the fusion protein with no loss of
to synthetic pre-S(120-145) (e) antisera to the pre-S deter-
of HBV particles (o), rabbit, or control rabbit serum (a ~ enzyme activity. The purified pre-S2-Gal ran as a single band
of each serum was 1:200. Assay details are given in with slightly slower electrophoretic mobility than 83-galac-
'sand Methods. tosidase on analytical NaDodSO4/polyacrylamide gels. It
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FIG. 3. (A) Inhibition of binding of anti-pre-S(120-145) to pre-S2-Gal by synthetic pre-S(120-145) (o) or by HBV particles (o). Twenty
microliters of lysate from JM83/pWS1 cells was used per test and the dilution of the anti-pre-S(120-145) antiserum was 1:200. (B) Inhibition
of binding of antibodies to the pre-S determinants of HBV to pre-S2-Gal by synthetic pre-S(120-145) (o) or by HBV particles (o). Twenty
microliters of lysate from JM83/pWS1 cells was used per test and the dilution of the antiserum was 1:300.
was virtually the only protein detectable by C4
staining (Fig. 4c, lane 1).
DISCUSSION
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oomassie blue Pre-S2-Gal produced in E. coli is recognized both by
antibodies raised against the pre-S2 region of HBV and
against synthetic pre-S(120-145) peptide. Furthermore, bind-
ing of these antibodies to the fusion protein is completely
inhibited by an appropriate concentration of either pre-
by the pre-S S(120-145) or HBV particles. These results clearly demon-
l inproteins of strate that the same or similar antigenic determinants are
ithetic peptide present in the 26 amino acid NH2-terminal sequence ofpre-S2
thin the pre-S regardless of whether it is in the form of a free peptide,
ytesand carry comprises the NH2 terminus of a native viral envelope
volvednu etiC- protein or is embedded in the NH2-terminal region of a
is, production functional ,B-galactosidase tetramer. They also suggest that
qfuencesyofthe the NH2-terminal half of pre-S2 is immunologically domi-
e life cycle of nant-i.e., that the contribution ofthe COOH-terminal halfof
pre-S2 (amino acids 146-174) to the antigenicity and im-
munogenicity of the HBV envelope proteins is comparatively
C small. However, antibodies to a synthetic peptide with the
2 amino acid sequence of the COOH-terminal half of pre-S2
200 153-171) recognize antigenic pres-
ent in native HBsAg (24), and the possibility remains that the
pre-S2 region of native viral envelope proteins contains
-116
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FIG. 4. NaDodSO4/polyacrylamide gel electrophoretic analysis
pre-S2-Gal from M182/pWS3 cells. (a) Lane 1, lysate from M182
cells; lane 2, lysate from equivalent volume of M182/pWS3 cells
containing 175 units of fgalactosidase activity. (b) Lane 1, anti-pre-
S(120-145) immunoprecipitate oflysate from M182/pWS3 cells (1750
units of f-galactosidase activity); lane 2, anti-pre-S(120-145) immu-
noprecipitate of lysate from M182/pSKS105 cells (1750 units of
,-galactosidase activity); (c) lane 1, affinity purified pre-S2-Gal
fusion protein from M182/pWS3 cells (120 units of A-galactosidase
activity from the purification presented in Table 3); lane 2, molecular
weight markers (X 10-3).
Table 2. Affinity purification of pre-S2-Gal
-3-Galactosidase, Specific activity,
Fraction Protein, mg units* units/mg
Load 517 300,000 580
Wash 450 >0.3 0
Borate eluate 6.9 300,000 43,000
Data shown are from a representative experiment in which a lysate
containing 300,000 units of 3-galactosidase diluted in buffer contain-
ing 1.6M NaCl, 20mM Tris HCl (pH 7.4), 10mM MgCl2, and 10mM
2-mercaptoethanol was passed over a 6-ml column packed with
p-aminophenyl-,-D-thiogalactoside-Sepharose equilibrated with the
same buffer. The column was washed with this buffer until no more
protein was eluted and was then eluted with 100 mM sodium borate,
pH 10/10 mM 2-mercaptoethanol (21). The values given for total
enzyme activity and protein content were calculated from assays of
3-galactosidase activity in aliquots of the fractions and from their
absorbance at 280 nm. In four separate experiments, recovery of
total protein ranged from 85% to 95% and recovery of pre-S2-Gal
ranged from 95% to 100o. Recovered purified pre-S2-Gal comprised
1%-3% of the total protein in the lysates.
*A unit of /3galactosidase is defined as the amount capable of
hydrolyzing 1 nmol of o-nitrophenyl-f3-D-galactopyranoside per min
at 28°C.
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additional antigenic determinants that are not represented' in
either pre-S(120-145) or in pre-S2-Gal.
It should be noted that the synthetic pre-S(120-145) used
in these studies has the amino acid sequence of an adw
serotype. Nevertheless, antibodies to this peptide bind equal-
ly well with the pre-S2 amino acid sequence encoded in the
genome of a virus with serotype ayw. This conclusion is
supported by the observation that estimations of the concen-
trations of pre-S2-Gal in lysates of M182/pWS3 cells are
approximately the same whether based on the assumption
that anti-pre-S(120-145) has an equivalent binding capacity
for pre-S(120-145) and the corresponding region of pre-
S2-Gal or are calculated from the (-galactosidase activity of
the fusion protein. Similarly, if one considers that pre-
S(120-145) sequences constitute =1% of the mass of HBV
envelope proteins (8), the inhibition studies shown in Fig. 3B
indicate that the binding capacity of antibodies to the pre-S
region of native HBV envelope proteins is equivalent in
molar terms for pre-S(120-145), pre-S2-Gal, and HBV.
The results presented here demonstrate that pre-S2, which
shares antigenic determinants with pre-S2 in native HBV
envelope proteins, can be synthesized in large amounts in E.
coli. They also indicate the feasibility of using expression
vectors to direct bacterial synthesis of fusion proteins con-
taining both an antigenic determinant and a marker enzyme
suitable for use in ELISA tests. It seems highly likely that
other preselected sequences of the pre-S region can be
synthesized as fusion proteins through use of the same or
similar expression vectors. The availability of these proteins
will certainly lead to unique reagents for diagnosis of HBV
infection. However, if pre-S fusion proteins also prove to be
immunogenic and/or to directly affect interaction of HBV
with hepatocytes, they have the potential for contributing to
a further definition of the role of the minor HBV envelope
proteins carrying pre-S region domains, and they may aid in
the development of new or improved modalities for active
prophylaxis of HBV.
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